Valproate-Associated Parkinsonism: A Critical Review of the Literature

CNS Drugs

Volumn 30, Issue 6, 2016, Pages 527-540

  Brugger, Florian ^a,b   Bhatia, Kailash P ^a   Besag, Frank M C ^c,d,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c EAST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTRANSMITTER; VALPROIC ACID; ANTICONVULSIVE AGENT; DOPAMINE; DOPAMINE TRANSPORTER;

CLINICAL FEATURE; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; GENE EXPRESSION; HUMAN; NARANJO SCORE; NERVE DEGENERATION; NEUROIMAGING; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; DRUG EFFECTS; MIGRAINE DISORDERS; PARKINSONIAN DISORDERS;

ANTICONVULSANTS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MIGRAINE DISORDERS; PARKINSONIAN DISORDERS; VALPROIC ACID;

EID: 84973117945     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0341-8     Document Type: Review

References (68)

1. Peterson GM, Naunton M. Valproate: a simple chemical with so much to offer. J Clin Pharm Ther. 2005;30:417–21.
2. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010611.
3. Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders–a population-based study of prescriptions. Epilepsy Res 2009;87:31–9.
4. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci. 2007;64:2090–103.
5. Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int. 2000;37:103–10.
6. Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994;47:332–72.
7. Karas BJ, Wilder BJ, Hammond EJ, Bauman AW. Valproate tremors. Neurology. 1982;32:428–32.
8. Lewis C, Deshpande A, Tesar GE, Dale R. Valproate-induced hyperammonemic encephalopathy: a brief review. Curr Med Res Opin. 2012;28:1039–42.
9. Mattson RH, Cramer JA. Tremor due to sodium valproate. Neurology. 1981;31:114.
10. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765–771.
11. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16:695–714.
12. Lautin A, Stanley M, Angrist B, Gershon S. Extrapyramidal syndrome with sodium valproate. Br Med J. 1979;2:1035–6.
13. Mahmoud F, Tampi RR. Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature. Am J Geriatr Pharmacother. 2011;9:405–12.
14. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25:2649–53.
15. American Academy of Neurology. Clinical practice guidelines process manual. 2011th ed. St. Paul: The American Academy of Neurology; 2011.
16. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.
17. Jamora D, Lim SH, Pan A, Tan L, Tan EK. Valproate-induced parkinsonism in epilepsy patients. Mov Disord. 2007;22:130–3.
18. Zadikoff C, Munhoz RP, Asante AN, Politzer N, Wennberg R, Carlen P, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry. 2007;78:147–51.
19. Easterford K, Clough P, Kellett M, Fallon K, Duncan S. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology. 2004;62:1435–7.
20. Alvarez-Gomez MJ, Vaamonde J, Narbona J, Barao M, Barona P, Brannan T, et al. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol. 1993;16:451–5.
21. Froomes PR, Stewart MR. A reversible parkinsonian syndrome and hepatotoxcity following addition of carbamazepine to sodium valproate. Aust N Z J Med. 1994;24:413–4.
22. Desai DS, Desai SD. Spectrum of disorders presenting as secondary Parkinsonism in a rural based medical teaching college in Western India [abstract]. Mov Disord 2015;30 Suppl 1:794.
23. Irons R, Joanna BM, Apurba CK. The role of DaT scan in drug induced Parkinsonism [abstract]. Mov Disord 2015;30 Suppl 1:997.
24. Scherrer MJ, Zieglgänsberger D, Kapauer B, Tettenborn B. Valproate-induced parkinsonism in epilepsy patient [poster no. P57]. Joint Annual Meeting 2014, Swiss Neurological Society; 29 Oct 2014; Interlaken. Swiss Medical Forum 2014;Suppl. 62:80.
25. Wils V, Goluke-Willemse G. Extrapyramidal syndrome due to valproate administration as an adjunct to lithium in an elderly manic patient. Int J Geriatr Psychiatry. 1997;12:272.
26. Evans MD, Shinar R, Yaari R. Reversible dementia and gait disturbance after prolonged use of valproic acid. Seizure. 2011;20:509–11.
27. Gaubert ML, Cougnaud A, Ghali A, Bruhat C, Diquet B, Berrut G. Loss of autonomy related to valproic acid intake [letter]. J Am Geriatr Soc. 2006;54:1971.
28. Macphee GJ, Stewart DA. Diagnosis of Parkinsonism in older patients receiving sodium valproate [letter]. Mov Disord. 2007;22:1211.
29. Shill HA, Fife TD. Valproic acid toxicity mimicking multiple system atrophy. Neurology. 2000;55:1936–7.
30. Borroni B, Rosati A, Costanzi C, Zulli R, Mardighian D, Gasparotti R, et al. Multiple system atrophy due to prolonged valproic acid treatment. Int Psychogeriatr. 2007;19:780–2.
31. Iijima M. Valproate-induced parkinsonism in a demented elderly patient. J Clin Psychiatry. 2002;63:75.
32. Athauda D, Batley R, Ellis C. Clinically silent idiopathic Parkinson’s disease unmasked by valproate use: a brief report. Aging Clin Exp Res. 2015;27:387–90.
33. De Dios C, Fudio S, Lorenzo A. Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine. J Clin Pharm Ther. 2011;36:430–2.
34. Sleegers MJ, Beutler JJ, Hardon WJ, Berden JH, Verhave JC, Conemans JM, et al. Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus. J Am Geriatr Soc. 2010;58:799–801.
35. Salazar Z, Tschopp L, Calandra C, Micheli F. Pisa syndrome and parkinsonism secondary to valproic acid in Huntington’s disease. Mov Disord. 2008;23:2430–1.
36. Maxikov KG, Maxikov GK. Valproate-induced parkinsonism in epilepsy patient - a case report. Acta Medica Bulgarica. 2008;35:38–42.
37. Tada H, Ogihara T, Nakamura T, Sasayama D, Sugiyama N, Takahashi Y, et al. A case of severe parkinsonism in an elderly person induced by valproic acid. Psychogeriatrics. doi:10.1111/psyg.12172 (Epub 2016 Jan 12)
38. Khwaja GA, Ranjan R, Gupta M, Chowdhry D, Hirva M. Valproate-induced reversible ‘Parkinsonism Plus’ syndrome. J Ind Acad Clin Med. 2010;11:235–8.
39. Onofrj M, Thomas A, Paci C. Reversible parkinsonism induced by prolonged treatment with valproate. J Neurol. 1998;245:794–6.
40. Sasso E, Delsoldato S, Negrotti A, Mancia D. Reversible valproate-induced extrapyramidal disorders. Epilepsia. 1994;35:391–3.
41. Masmoudi K, Gras-Champel V, Masson H, Andrejak M. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry. 2006;39:9–12.
42. Silver M, Factor SA. Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. Parkinsonism Relat Disord. 2013;19:758–60.
43. Munhoz RP, Werneck LC, Teive HA. The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. Clin Neurol Neurosurg. 2010;112:431–5.
44. Armon C, Shin C, Miller P, Carwile S, Brown E, Edinger JD, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology. 1996;47:626–35.
45. Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26:2226–31.
46. Ristic AJ, Vojvodic N, Jankovic S, Sindelic A, Sokic D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia. 2006;47:2183–5.
47. Nouzeilles M, Garcia M, Rabinowicz A, Merello M. Prospective evaluation of parkinsonism and tremor in patients treated with valproate. Parkinsonism Relat Disord. 1999;5:67–8.
48. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239–76.
49. Movement Disorder Society Task Force on Rating Scales for Parkinson’s D. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738–50.
50. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097
51. Erro R, Bhatia KP, Tinazzi M. Parkinsonism following neuroleptic exposure: a double-hit hypothesis? Mov Disord. 2015;30:780–5.
52. Paladini CA, Celada P, Tepper JM. Striatal, pallidal, and pars reticulata evoked inhibition of nigrostriatal dopaminergic neurons is mediated by GABA(A) receptors in vivo. Neuroscience. 1999;89:799–812.
53. Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci. 2014;17:1022–30.
54. Maneuf YP, Mitchell IJ, Crossman AR, Brotchie JM. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol. 1994;125:65–71.
55. Bruni J, Wilder BJ, Willmore LJ, Perchalski RJ, Villarreal HJ. Steady-state kinetics of valproic acid in epileptic patients. Clin Pharmacol Ther. 1978;24:324–32.
56. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem. 2001;276:31674–83.
57. Chen G, Manji HK. The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr Opin Psychiatry. 2006;19:313–23.
58. Deslauriers J, Desmarais C, Sarret P, Grignon S. Implication of the ERK/MAPK pathway in antipsychotics-induced dopamine D2 receptor upregulation and in the preventive effects of (+/−)-alpha-lipoic acid in SH-SY5Y neuroblastoma cells. J Mol Neurosci. 2014;52:378–83.
59. Green AL, Hossain MM, Tee SC, Zarbl H, Guo GL, Richardson JR. Epigenetic regulation of dopamine transporter mRNA expression in human neuroblastoma cells. Neurochem Res. 2015;40:1372–8.
60. Lee S, Jeong J, Park YU, Kwak Y, Lee SA, Lee H, et al. Valproate alters dopamine signaling in association with induction of Par-4 protein expression. PLoS One. 2012;7:e45618.
61. Silva MF, Aires CC, Luis PB, Ruiter JP, IJlst L, Duran M, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 2008;31:205–16
62. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011;8:267–80.
63. Moon HE, Paek SH. Mitochondrial dysfunction in Parkinson’s disease. Exp Neurobiol. 2015;24:103–16.
64. Lebre AS, Rio M, Faivre d’Arcier L, Vernerey D, Landrieu P, Slama A, et al. A common pattern of brain MRI imaging in mitochondrial diseases with complex I deficiency. J Med Genet 2011;48:16–23.
65. Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81:5–12.
66. Mahlknecht P, Seppi K, Frauscher B, Kiechl S, Willeit J, Stockner H, et al. Probable RBD and association with neurodegenerative disease markers: a population-based study. Mov Disord. 2015;30:1417–21.
67. Spatola M, Wider C. Genetics of Parkinson’s disease: the yield. Parkinsonism Relat Disord. 2014;20(Suppl 1):S35–8.
68. Postuma RB, Gagnon JF, Bertrand JA, Genier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015;84:1104–13